Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Coherus Partners Formycon/Bioeq File Ranibizumab With FDA

Company ‘Excited For Potential Approval In 2022’ For Lucentis Biosimilar

Executive Summary

Launch planning is underway for the Lucentis biosimilar that Coherus BioScienes has in-licensed in the US from Formycon and Bioeq, the US-based firm has revealed, as the eye-disease biologic was submitted to the US Food and Drug Administration.

You may also be interested in...



What’s Next? Five Things To Look Out For In December

As 2021 draws to a close, Coherus BioSciences awaits word on its FDA filing for biosimilar Humira, while Pfizer plots a submission for a designation for interchangeability, aiming to emulate that enjoyed by Boehringer Ingelheim’s Cyltezo. Aurobindo will also plan for the exit of popular managing director Narayanan Govindarajan.

Coherus Insists Demand Is ‘Pent Up’ For On-Body Pegfilgrastim Biosimilar

California-Based Coherus BioSciences delved further into its plans and expectations for its proposed proprietary pegfilgrastim on-body device, as it also detailed continued pricing challenges for the pre-filled syringe formulation.

Coherus Awaits August 2022 Date As FDA Accepts Ranibizumab Biosimilar

The US FDA has accepted for review the CHS-201 Lucentis biosimilar product developed by Formycon/Bioeq that is to be sold in the US by Coherus BioSciences, shortly after approving the first ranibizumab biosimilar to treat wet age-related macular degeneration.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

GB151160

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel